Compare Stocks: INO, MRNA, RGNX, and CABA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CABA Cabaletta Bio	$3.35 -3.6%	$2.96	$1.63 ▼ $4.23	$567.11M	3.27	3.85 million shs	1.59 million shs
INO Inovio Pharmaceuticals	$1.43 -0.3%	$1.09	$0.56 ▼ $2.98	$147.35M	1.63	2.58 million shs	2.16 million shs
MRNA Moderna	$142.34 -2.2%	$87.26	$22.28 ▼ $176.66	$56.87B	1.1	11.61 million shs	6.58 million shs
RGNX REGENXBIO	$8.81 -1.5%	$10.95	$5.45 ▼ $16.19	$581.91M	0.94	1.43 million shs	435,589 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CABA Cabaletta Bio	0.00%	+11.58%	+24.37%	+7.76%	+104.12%
INO Inovio Pharmaceuticals	0.00%	+12.60%	+114.07%	+30.00%	-48.75%
MRNA Moderna	0.00%	+3.71%	+145.99%	+204.94%	+478.96%
RGNX REGENXBIO	0.00%	-5.89%	-16.60%	+41.01%	-7.93%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CABA Cabaletta Bio	$3.35 -3.6%	$2.96	$1.63 ▼ $4.23	$567.11M	3.27	3.85 million shs	1.59 million shs
INO Inovio Pharmaceuticals	$1.43 -0.3%	$1.09	$0.56 ▼ $2.98	$147.35M	1.63	2.58 million shs	2.16 million shs
MRNA Moderna	$142.34 -2.2%	$87.26	$22.28 ▼ $176.66	$56.87B	1.1	11.61 million shs	6.58 million shs
RGNX REGENXBIO	$8.81 -1.5%	$10.95	$5.45 ▼ $16.19	$581.91M	0.94	1.43 million shs	435,589 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CABA Cabaletta Bio	0.00%	+11.58%	+24.37%	+7.76%	+104.12%
INO Inovio Pharmaceuticals	0.00%	+12.60%	+114.07%	+30.00%	-48.75%
MRNA Moderna	0.00%	+3.71%	+145.99%	+204.94%	+478.96%
RGNX REGENXBIO	0.00%	-5.89%	-16.60%	+41.01%	-7.93%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CABA Cabaletta Bio	2.75	Moderate Buy	$15.33	358.40% Upside
INO Inovio Pharmaceuticals	2.75	Moderate Buy	$3.17	122.22% Upside
MRNA Moderna	2.08	Hold	$76.72	-46.10% Downside
RGNX REGENXBIO	2.62	Moderate Buy	$23.27	164.16% Upside

Current Analyst Ratings Breakdown

Latest INO, MRNA, RGNX, and CABA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/4/2026	RGNX REGENXBIO	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/3/2026	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$81.00
9/3/2026	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Sell
9/3/2026	MRNA Moderna	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Neutral ➝ Sell	$40.00 ➝ $81.00
9/1/2026	CABA Cabaletta Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$16.00
8/28/2026	MRNA Moderna	CLSA Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Outperform
8/28/2026	MRNA Moderna	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold
8/28/2026	MRNA Moderna	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
8/28/2026	MRNA Moderna	Bradesco Corretora Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Outperform
8/28/2026	MRNA Moderna	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$180.00
8/25/2026	MRNA Moderna	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Underperform ➝ Peer Perform

(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	$1.16 per share	N/A
INO Inovio Pharmaceuticals	$60K	2,455.75	N/A	N/A	$0.36 per share	3.96
MRNA Moderna	$1.94B	29.23	N/A	N/A	$22.14 per share	6.43
RGNX REGENXBIO	$174.48M	3.33	N/A	N/A	$2.03 per share	4.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CABA Cabaletta Bio	-$167.86M	-$1.57	N/A	N/A	N/A	N/A	-128.27%	-95.47%	11/9/2026 (Estimated)
INO Inovio Pharmaceuticals	-$84.95M	-$0.91	N/A	N/A	N/A	N/A	-669.94%	-73.97%	11/10/2026 (Estimated)
MRNA Moderna	-$2.82B	-$7.99	N/A	N/A	N/A	-141.43%	-28.30%	-19.39%	11/5/2026 (Estimated)
RGNX REGENXBIO	-$193.88M	-$3.79	N/A	N/A	N/A	-112.58%	-220.07%	-46.04%	11/5/2026 (Estimated)

Latest INO, MRNA, RGNX, and CABA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CABA Cabaletta Bio	-$0.3729	-$0.34	+$0.0329	-$0.34	$1.67 million	N/A
8/12/2026	Q2 2026	INO Inovio Pharmaceuticals	-$0.2167	-$0.07	+$0.1467	-$0.07	$0.53 million	N/A
8/6/2026	Q2 2026	RGNX REGENXBIO	$0.0787	$0.43	+$0.3513	$0.43	$97.63 million	$108.02 million
7/31/2026	Q2 2026	MRNA Moderna	-$2.03	-$1.97	+$0.06	-$1.97	$102.93 million	$145.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	N/A
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CABA Cabaletta Bio	N/A	5.79	5.79
INO Inovio Pharmaceuticals	N/A	1.00	1.00
MRNA Moderna	0.09	2.29	2.18
RGNX REGENXBIO	N/A	2.86	2.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CABA Cabaletta Bio	N/A
INO Inovio Pharmaceuticals	26.79%
MRNA Moderna	75.33%
RGNX REGENXBIO	88.08%

Insider Ownership

Company	Insider Ownership
CABA Cabaletta Bio	6.44%
INO Inovio Pharmaceuticals	1.70%
MRNA Moderna	10.80%
RGNX REGENXBIO	14.22%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CABA Cabaletta Bio	50	169.54 million	158.63 million	Optionable
INO Inovio Pharmaceuticals	320	103.40 million	101.64 million	Optionable
MRNA Moderna	4,700	399.24 million	356.12 million	Optionable
RGNX REGENXBIO	370	66.01 million	56.63 million	Optionable

INO, MRNA, RGNX, and CABA Headlines

Recent News About These Companies

REGENXBIO to Participate in Upcoming Investor Conferences

September 8 at 7:05 AM | prnewswire.com

Regenxbio’s Gene Therapy Faces Another FDA Setback in Hunter Syndrome

September 4, 2026 | insidermonkey.com

Corient Private Wealth LP Purchases New Stake in REGENXBIO Inc. $RGNX

September 3, 2026 | marketbeat.com

REGENXBIO (NASDAQ:RGNX) Trading Down 4.8% - Time to Sell?

August 31, 2026 | marketbeat.com

6,397,440 Shares in REGENXBIO Inc. $RGNX Bought by BlackRock Inc.

August 31, 2026 | marketbeat.com

REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Recommendation of "Moderate Buy" from Analysts

August 29, 2026 | americanbankingnews.com

REGENXBIO Inc. (NASDAQ:RGNX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

August 29, 2026 | marketbeat.com

REGENXBIO (NASDAQ:RGNX) Shares Gap Up - Still a Buy?

August 28, 2026 | marketbeat.com

Deutsche Bank AG Invests $2.49 Million in REGENXBIO Inc. $RGNX

August 28, 2026 | marketbeat.com

REGENXBIO Director Gregory Ciongoli Discloses Multiple Stock Purchases and Option Grant in August 2026

August 28, 2026 | kalkinemedia.comK

Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX) and Ansell (OtherANSLF)

August 27, 2026 | theglobeandmail.com

Ieq Capital LLC Buys Shares of 141,469 REGENXBIO Inc. $RGNX

August 26, 2026 | marketbeat.com

Regenxbio’s RGX-121 setback carries a potential cash risk, warns Clear Street

August 26, 2026 | msn.com

Regenxbio: Sell-Off On Hunter Setback Presents A Risky Buy Opportunity

August 26, 2026 | seekingalpha.com

RegenXBio reshapes board with new independent director

August 25, 2026 | tipranks.com

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX)

August 25, 2026 | businesswire.com

REGENXBIO (NASDAQ:RGNX) Shares Up 7.5% - Here's Why

August 25, 2026 | marketbeat.com

RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy

August 25, 2026 | zacks.com

REGENXBIO (NASDAQ:RGNX) Price Target Lowered to $21.00 at HC Wainwright

August 25, 2026 | marketbeat.com

REGENXBIO (NASDAQ:RGNX) Price Target Cut to $29.00 by Analysts at Robert W. Baird

August 25, 2026 | marketbeat.com

REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli

August 25, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

INO, MRNA, RGNX, and CABA Company Descriptions

Cabaletta Bio NASDAQ:CABA

$3.34 -0.13 (-3.60%)

As of 02:24 PM Eastern

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Inovio Pharmaceuticals NASDAQ:INO

$1.42 -0.01 (-0.35%)

As of 02:24 PM Eastern

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Moderna NASDAQ:MRNA

$142.34 -3.21 (-2.21%)

As of 02:24 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

REGENXBIO NASDAQ:RGNX

$8.81 -0.13 (-1.45%)

As of 02:23 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INO, MRNA, RGNX, and CABA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INO, MRNA, RGNX, and CABA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INO, MRNA, RGNX, and CABA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

INO, MRNA, RGNX, and CABA Company Descriptions

Cabaletta Bio NASDAQ:CABA

Inovio Pharmaceuticals NASDAQ:INO

Moderna NASDAQ:MRNA

REGENXBIO NASDAQ:RGNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INO, MRNA, RGNX, and CABA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INO, MRNA, RGNX, and CABA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INO, MRNA, RGNX, and CABA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

INO, MRNA, RGNX, and CABA Company Descriptions

Cabaletta Bio NASDAQ:CABA

Inovio Pharmaceuticals NASDAQ:INO

Moderna NASDAQ:MRNA

REGENXBIO NASDAQ:RGNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools